Zydus receives final approval for Olmesartan Medoxomil Tablets

From USFDA

Zydus Cadila has received the final approval from the USFDA to market Olmesartan Medoxomil Tablets in strengths of 5 mg, 20 mg and 40 mg. This is a day one approval after the expiry of 181 day exclusivity. The drug is an anti-hypersensitive and will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

Powered by Capital Market - Live News